TrialWatch: Bavencio Shows Real Promise in Phase I Trial for Malignant Mesothelioma Patients

Feb 13, 2019 | Checkpoint Inhibitors, Malignant Mesothelioma,, Oncology, Positive Results

Malignant Mesothelioma,

Immuno-Oncology News’ Ines Martins reports Merck KGaA (operating as EMD Serono in the U.S.) and Pfizer’s jointly developed immune checkpoint inhibitor Bavencio (avelumab) shows durable clinical activity and long-term disease control among heavily pretreated malignant mesothelioma patients according to recent Phase I clinical trial information.  According to early data, the drug controlled the disease in 58% of patients, with 17% living without disease worsening for one year or longer. The findings were published in JAMA Oncology. The clinical trial was described as a Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications.


Pin It on Pinterest